跳至主要内容
临床试验/JPRN-UMIN000012774
JPRN-UMIN000012774已完成1 期

A phase I/II study for peptides cocktail vaccine in patients with progressive or recurrent malignant glioma. - Peptides cocktail vaccine for patients with progressive or recurrent malignant glioma.

Department of Neurosurgery, Keio University School of Medicine0 个研究点目标入组 20 人开始时间: 2014年1月8日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
16years-old 至 79years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Uncontrollable severe infectious diseases. 2) Serious concomitant diseases 3) Adverse event of NCI-CTC grade 3 or 4. 4) Unable to take anything orally over 24 hours. 5) Active multiple cancers. 6) Myeloproliferative diseases such as MDS and CML. 7) After allogeneic hematopoietic stem cell transplantation. 8) Active autoimmune diseases. 9) Severe drug allergy 10) Necessity for administration of steroid or immunosuppressive drugs. 11) Pregnancy or lactation. Patients hope pregnancy 12) Psychiatric disorders. 13) Unhealed injury. 14) Judged as inappropriate for this study by doctors.

研究者

发起方
Department of Neurosurgery, Keio University School of Medicine

相似试验

已完成
不适用
Phase 2a study of peptide cocktail vaccine and interferon-beta for patients with refractory pediatric central nervous system tumorrefractory pediatric central nervous system tumors
JPRN-UMIN000032774Osaka City General Hospital13
已完成
1 期
Phase I study of peptide-cocktail vaccination for HCV-positive patients with liver cancer who have undergone radical therapy.liver cancer
JPRN-UMIN000003773Kurume University Cancer Vaccine Center3
进行中(未招募)
1 期
Anti-tumoral vaccination of melanoma patients with peptides associated with GM-CT-01, a vegetal derived sugar that binds to and blocks galectin, a protein produced by tumor cells that inhibits immune cells.Metastatic melanomaMedDRA version: 14.0Level: LLTClassification code 10025651Term: Malignant melanoma excisionSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.0Level: LLTClassification code 10027150Term: Melanoma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10042550Term: Superficial spreading melanoma stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10029488Term: Nodular melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10025662Term: Malignant melanoma of skin of scalp and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10040891Term: Skin melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10056768Term: Malignant melanoma of skin of lower limb, incl hipSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10048434Term: Melanoma malignant aggravatedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10042548Term: Superficial spreading melanoma in situSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10025652Term: Malignant melanoma in situSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2010-018638-29-BECentre du Cancer des Cliniques Universitaires Saint-Luc6
进行中(未招募)
1 期
Phase I/II study of peptide vaccination associated with tumoral immunomodulation with proinflammatory cytokines and imiquimod in patients with advanced metastatic melanoma
EUCTR2010-020435-40-BECentre du Cancer3
已完成
1 期
A combination phase I trial of peptide vaccines and Docetaxel/5'-DFUR in patients with advanced or recurrent gastric cancerAdvanced or recurrent gastric cancer
JPRN-UMIN000009751Yamaguchi University Graduate School of Medicine, Digestive surgery and surgical oncology9